System Requirements

Program Faculty

Faculty Disclosure

Accreditation and Educational Credit

Statement of Educational Need

Educational Objectives

Statement of Evaluation Instrument

Statement of Intended, or Target, Audience

Acknowledgement of Commercial Support
 

References


1. Siris E. Alendronate in the treatment of osteoporosis: a review of the clinical trials. J Women's Health Gender-Based Med. 2000;9(6): 599-606.

2. Schurch M, Rizzoli R, Mermillod B, et al. A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res. 1996;11:1935-1342.

3. Ahlborg HG, Johnell O, Nilsson BE, et al. Bone loss in relation to menopause: a prospective study during 16 years. Bone. 2001;28(3):327-331.

4. Marshall D, Johnell O,Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J. 1996;312:1254-1259.

5. Kanis J, WHO Study Group. Assessment of fracture risk and its application to screening for osteoporosis: Synopsis of a WHO report. Osteoporosis Int. 1994;4:368-381.

6. Lacey JV Jr, Mink PJ, Lubin JH. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 2002;288:334-341.

7. Shea B, Wells G, Cranney A, et al. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocrine Rev. 2002;23(4):552-559.

8. Chapuy MC, Arlot ME, Delmas PD, et al. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Br J Med. 1994;308(6936): 1081-1082.

9. Lips P, Graafmans WC, Ooms ME, et al. Vitamin D supplementation and fracture incidence in elderly persons. Ann Intern Med. 1996;124:400-406.

10. Kiel DP, Felson DT, Anderson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women: The Framingham Study. N Engl J Med. 1987;317(19):1169-1174.

11. Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med. 1999;130:431-439.

12. Cranney A, Tugewell P, Zytaruk N, et al. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocrine Rev. 2002;23(4): 524-528.

13. Ettinger B, Black D, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial: Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637-645.

14. Plosker GL, McTavish D. Intranasal calcitonin: a review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging. 1996;8:378-400.

15. Takahashi S, Goldring S, Katz M. Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest. 1995;95:165-171.

16. Eddy DM.Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporosis Int. 1998;S1-S88.

17. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocrine Rev. 2002;23(4):540-551.

18. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. Am J Med. 2000;109:267-276.

19. Cranney A,Wells G, Willan A, et al. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocrine Rev. 2002;23(4):508-516.

20. Black DM, Thompson DE, Bauer DC. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab. 2000;85(11):4118-4124.

21. Cranney A, Tugwell P, Adachi J, et al. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocrine Rev. 2002;23(4):517-523.

22. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA. 1999;282(14):1344-1352.

23. Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int. 2000;11:83-91.

24. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344(5):333-340.

25. Cranney A, Guyatt G, Griffith L, et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocrine Rev. 2002;23(4):570-578.

26. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-1441.